

Synthesis and Characterization of 2-phenyl-5-(1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl) - 1, 3, 4-oxadiazole Scaffolds for Assessing Their Medicinal Potentials

Krishna Prasad Chennapragada^{1,2}, Venkata Sathya Machiraju Palagummi^{3,*}

¹Department of Chemistry, Jawaharlal Nehru Technological University, Kakinada, Andhra Pradesh, INDIA.

²Escientia Bio Pharma Pvt Ltd, ICICI Knowledge Park, Hyderabad, Telangana, INDIA.

³Department of Chemistry, Pragati Engineering College (A), Surampalem, Andhra Pradesh, INDIA.

ABSTRACT

Objective: The present research is aimed at the discovery and development of 1-phenyl-3-(3,4,5-trimethoxyphenyl)-1H-pyrazole derivatives as a series of novel 1, 3, 4-oxadiazoles (7a-7h) through iodine-catalyzed oxidative cyclization of the hydrazone derivatives (6a-6h) in the presence of potassium carbonate as base and DMSO as solvent in good to excellent yields. **Methods:** The structures of all the newly synthesized compounds (6a-6h) and (7a-7h) were well characterized by IR, ¹H NMR, ¹³C NMR and HRMS. Furthermore, all the synthesized compounds (6a-6h and 7a-7h) were evaluated for their antimicrobial and anti-oxidant activities. **Results:** The research results revealed that the compound 6d (Z)-2-bromo-N'-((1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl) methylene) benzohydrazide has antimicrobial potent while the synthesized compounds 6a (Z)-N'-((1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl) methylene) benzohydrazide, 6e (Z)-2, 5-dichloro-N'-((1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl) methylene) benzohydrazide, 7e (2-(2, 5-dichlorophenyl)-5-(1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl)-1, 3, 4-oxadiazole) and 7f (2-(3, 5-dichlorophenyl)-5-(1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl)-1, 3, 4-oxadiazole) exhibited strong antioxidant activity compared to the control BHT. **Conclusion:** The novel hydrazone synthesized and 1, 3, 4-oxadiazole derivatives may be suggested for their establishment in chemical class of antimicrobial and antioxidant agents in new drug discovery and medicinal research.

Key words: Hydrazones, Oxadiazoles, Pyrazole, Anti-microbial, Anti-oxidant activity.

INTRODUCTION

The synthesis and biological evaluation of 1, 3, 4-oxadiazoles containing compounds have increased considerably in the last two decades. 1,3,4-Oxadiazole is an important heterocyclic compound which contains two carbons, two nitrogens, one oxygen atom and two double bonds in a five-membered ring with general formula C₂H₂ON₂. Potential pharmacological activity of 1, 3, 4-oxadiazoles is due to the presence of toxophoric -N=C-O- linkage which may react with the nucleophilic centres of the microbial cell. 1,3,4-Oxadiazole and its derivatives has attracted considerable attention in the medicinal, material and pes-

ticide chemistry.¹ The various biological and pharmaceutical properties possessed by this important structural motif has attracted the researchers for the development of new drug molecules.² The 1, 3, 4-oxadiazole compounds are generally synthesized by the oxidative cyclization of hydrazones which were prepared by the reaction of aromatic hydrazides with aromatic aldehydes. The various reagents employed for the oxidative cyclization of 1, 3, 4-Oxadiazole includes Lead tetraacetate, Lead dioxide, Potassium Permanganate, Chloramine-T, Ferric chloride and Iodobenzenediacetate. Examples of com-

Submission Date: 16-07-2017;

Revision Date: 25-09-2017;

Accepted Date: 10-01-2018

DOI: 10.5530/ijper.52.1.15

Correspondence:

Dr. P.V.S. Machiraju,

Dean R & D, Professor

Of Chemistry, Pragathi

Engineering College,

Surampalem-533437, Near

Kakinada, E.G.Dt, Andhra

Pradesh, INDIA.

Phone no: +91-9246691641

Email: drpvs.res@gmail.

com



www.ijper.org

60 F24 of Merck pre-coated plates were employed for their thin layer chromatography (TLC) analysis to check the purity of the compounds, the spot being located under UV light and iodine vapours.

Synthesis

The title compounds were synthesized by the following steps.

Synthesis of 1-(1-(3, 4, 5-trimethoxyphenyl) ethylidene)-2-phenylhydrazine (3).⁵⁰

To a solution of 1-(3, 4, 5-trimethoxyphenyl) ethanone **1** (5 g, 19 mmol) in methanol (40 mL) was added phenyl hydrazine **2** (2.1 g, 19 mmol) followed by glacial acetic acid (15 mL) at room temperature. The resulting reaction mixture was heated to reflux for 3 h. TLC showed completion of starting material (TLC System: 20% Ethylacetate in hexane, R_f : 0.5). The solvent was evaporated under reduced pressure, diluted with ice water (25 mL), stirred for 15 min at 10°C and filtered the precipitated solid, washed with ice water (20 mL) followed by n-pentane (20 mL) and dried under vacuum to afford 1-(1-(3, 4, 5-trimethoxyphenyl) ethylidene)-2-phenylhydrazine (**3**).

Synthesis of 3-(3, 4, 5-trimethoxyphenyl)-1-phenyl-1H-pyrazole-4 carbaldehyde (4).⁵¹

Phosphorus oxychloride (6.2 ml, 66 mmol) was added to N, N-Dimethylformamide (26.5 ml, 339 mmol) at -5 to 0°C drop wise over a period of 10 min, stirred at the same temperature for 30 min and added compound **3** (6.6 g, 22 mmol) dissolved in DMF (10 ml) dropwise at -5°C over a period of 15 min. The reaction mixture was allowed to warm to room temperature and stirred for 1.5 h. The completion of the reaction was monitored by TLC. After completion, the reaction mixture was slowly added to ice cold water and basified with saturated NaHCO₃ solution to adjust the pH 7-8, stirred for 1 h at room temperature and filtered the precipitated solid, washed with water and dried under vacuum to get the crude compound. The crude compound was washed with methanol, filtered and dried under vacuum to afford pure compound **4**.

General procedure for the synthesis of hydrazone derivatives 6a-6h.⁵²

A suspension of 1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazole-4-carbaldehyde **4** (0.44 mmol) and hydrazides (**5a-5h**) (0.44 mmol) in ethanol (7 mL) was heated to reflux for 7-8 h. After completion, the precipitated solid was filtered, washed with minimum amount of ethanol and dried under vacuum to obtain hydrazone derivatives (**6a-6h**).

General procedure for the synthesis of 1, 3,

4-oxadiazole derivatives 7a-7h.⁵³

To a stirred solution of compound (**6a-6h**) (0.22 mmol) in DMSO was added anhydrous K₂CO₃ (0.66 mmol) followed by Iodine (0.26 mmol) and heated to 100°C for 1 h. After completion of reaction, the reaction mixture was cooled to room temperature and treated with 5% Na₂S₂O₃ solution (5 ml), extracted with ethylacetate (25 ml). The organic layer was separated and washed with water and brine solution, dried over anhydrous Na₂SO₄, concentrated under reduced pressure to obtain the crude product. The crude solid product was washed with diethyl ether, filtered and dried under vacuum to afford oxadiazole derivatives (**7a-7h**).

The physicochemical and the spectral data of the synthesized compounds (6a-6h) and (7a-7h) are depicted as follows

(Z)-N'-((1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl) methylene) benzohydrazide (6a). Off-white solid, M.P: 213-215°C. Yield: 75%. Chemical formula: C₂₆H₂₄N₄O₄. FT-IR (KBr, cm⁻¹): 1649 (C=O), 1557 (C=N), 1125 (Ar-O). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 3.71 (*3.72, s, 3H, OCH₃), 3.87 (*3.82, s, 6H, 2OCH₃), 6.99 (*7.08, s, 2H, Ar-H), 7.36 (t, 1H, Ar-H, J = 7.2 Hz), 7.48–7.56 (m, 5H, Ar-H), 7.87 (d, 2H, Ar-H, J = 7.6 Hz), 8.01 (d, 2H, Ar-H, J = 8.0 Hz), 8.57 (*8.67, s, 1H, CH=N), 8.97 (*9.10, s, 1H, Pyrazole-H), 11.67 (br s, 1H, NH). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 56.02, 60.06, 106.02, 116.91, 118.89, 126.96, 127.44, 127.54, 128.43, 129.57, 131.62, 133.57, 137.88, 139.03, 141.16, 151.97, 152.99, 162.77. HRMS: Calculated for C₂₆H₂₄N₄O₄, 456.18, found: 457.1705 [M+H]⁺
(Z)-2-methyl-N'-((1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl) methylene) benzo-hydrazide (6b). Off-white solid, M.P: 206-208°C. Yield: 71%. Chemical formula: C₂₇H₂₆N₄O₄. FT-IR (KBr, cm⁻¹): 1651 (C=O), 1555 (C=N), 1127 (Ar-O). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.48 (s, 3H, Ar-CH₃), 3.70 (s, 3H, OCH₃), 3.86 (s, 6H, 2OCH₃), 6.98 (s, 2H, Ar-H), 7.25-7.29 (m, 2H, Ar-H), 7.30-7.42 (m, 3H, Ar-H), 7.53 (t, 2H, Ar-H, J = 7.76 Hz), 8.02 (d, 2H, Ar-H, J = 8.0 Hz), 8.44 (s, 1H, CH=N), 8.98 (s, 1H, Pyrazole-H), 11.59 (br s, 1H, NH). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 19.24, 56.00, 60.07, 105.89, 116.84, 118.86, 125.64, 126.97, 127.36, 127.42, 127.50, 129.60, 129.83, 130.58, 135.45, 135.78, 137.86, 139.03, 140.78, 151.81, 152.99, 164.82. HRMS: Calculated for C₂₇H₂₆N₄O₄, 470.20, found: 471.1907 [M+H]⁺
(Z)-3, 4, 5-trimethoxy-N'-((1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl) methylene) benzohydrazide (6c): Off-white solid, M.P: 203-205°C. Yield: 82%. Chemical formula: C₂₉H₃₀N₄O₇.

FT-IR (KBr, cm^{-1}): 1636 (C=O), 1583 (C=N), 1123 (Ar-O). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 3.71 (s, 6H, 2OCH₃), 3.84 (s, 6H, 2OCH₃), 3.87 (s, 6H, 2OCH₃), 7.01 (s, 2H, Ar-H), 7.18 (s, 2H, Ar-H), 7.38 (t, 1H, Ar-H, J = 7.2 Hz), 7.53 (t, 2H, Ar-H, J = 7.68 Hz), 8.02 (d, 2H, Ar-H, J = 8.08 Hz), 8.55 (s, 1H, CH=N), 8.99 (s, 1H, Pyrazole-H), 11.53 (br s, 1H, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 56.05, 56.13, 60.08, 60.13, 105.25, 106.10, 116.89, 118.91, 126.99, 127.46, 127.53, 128.79, 129.59, 137.94, 139.03, 140.39, 141.14, 151.95, 152.69, 153.01, 162.37. HRMS: Calculated for C₂₉H₃₀N₄O₇, 546.21, found: 547.1993 [M+H]⁺

(Z)-2-bromo-N'-((1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl) methylene) benzohydrazide (6d). Off-white solid, M.P: 177-179°C. Yield: 70%. Chemical formula: C₂₆H₂₃BrN₄O₄. FT-IR (KBr, cm^{-1}): 1648 (C=O), 1551 (C=N), 1127 (Ar-O). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 3.70 (*3.72, s, 3H, OCH₃), 3.86 (*3.84, s, 6H, 2OCH₃), 6.99 (*6.83, s, 2H, Ar-H), 7.35-7.41 (m, 2H, Ar-H), 7.42-7.56 (m, 4H, Ar-H), 7.72 (*7.63, d, 1H, Ar-H, J = 7.84), 8.02 (*7.83, d, 2H, Ar-H, J = 8.08), 8.41(*8.30, s, 1H, CH=N), 9.0 (s, 1H, Pyrazole-H), 11.72 (*11.81, br s, 1H, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 56.01, 60.07, 105.65, 105.89, 116.53, 116.61, 118.87, 119.07, 119.46, 126.26, 127.00, 127.18, 127.35, 127.74, 129.04, 129.26, 129.59, 130.61, 131.46, 132.16, 132.83, 137.47, 137.64, 137.88, 138.89, 139.00, 141.45, 151.72, 151.87, 152.99, 162.91, 168.66. HRMS: Calculated for C₂₆H₂₃BrN₄O₄, 534.09, found: 535.0853 [M+H]⁺

(Z)-2, 5-dichloro-N'-((1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl) methylene) benzohydrazide (6e). Off-white solid, M.P: 179-181°C. Yield: 76%. Chemical formula: C₂₆H₂₂Cl₂N₄O₄. FT-IR (KBr, cm^{-1}): 1654 (C=O), 1561 (C=N), 1127 (Ar-O). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 3.70 (*3.71, s, 3H, OCH₃), 3.86 (*3.83, s, 6H, 2OCH₃), 6.99 (*6.81, s, 2H, Ar-H), 7.35-7.39 (m, 1H, Ar-H), 7.50-7.59 (m, 4H, Ar-H), 7.71 (s, 1H, Ar-H), 8.02 (*7.86, d, 2H, Ar-H, J = 7.92 Hz), 8.40 (*8.23, s, 1H, CH=N), 9.01 (s, 1H, Pyrazole-H), 11.80 (*11.93, br s, 1H, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 56.02, 60.06, 105.66, 105.94, 116.47, 118.89, 119.09, 126.58, 127.03, 127.30, 127.83, 128.42, 128.66, 128.95, 129.31, 129.59, 130.34, 130.79, 131.14, 131.53, 131.87, 136.75, 137.90, 138.45, 138.97, 141.94, 151.77, 151.96, 152.98, 160.57, 166.51. HRMS: Calculated for C₂₆H₂₂Cl₂N₄O₄, 524.10, found: 525.0982 [M+H]⁺

(Z)-3, 5-dichloro-N'-((1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl) methylene) benzohydrazide (6f). Off-white solid, M.P: 224-226°C. Yield: 84%. Chemical formula: C₂₆H₂₂Cl₂N₄O₄. FT-IR

(KBr, cm^{-1}): 1686 (C=O), 1555 (C=N), 1120 (Ar-O). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 3.72 (s, 3H, OCH₃), 3.88 (s, 6H, 2OCH₃), 6.99 (s, 2H, Ar-H), 7.38 (t, 1H, Ar-H, J = 7.4 Hz), 7.54 (t, 2H, Ar-H, J = 7.76 Hz), 7.86-7.91 (m, 3H, Ar-H), 8.02 (d, 2H, Ar-H, J = 7.96 Hz), 8.54 (s, 1H, CH=N), 9.01 (s, 1H, Pyrazole-H), 11.80 (s, 1H, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 56.06, 60.07, 106.10, 116.64, 118.94, 126.34, 127.04, 127.35, 127.65, 129.58, 131.01, 134.39, 136.78, 137.96, 138.99, 142.24, 152.16, 153.00, 159.97. HRMS: Calculated for C₂₆H₂₂Cl₂N₄O₄, 524.10, found: 525.1005 [M+H]⁺

(Z)-3-nitro-N'-((1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl) methylene) benzohydrazide (6g): Pale yellow solid, M.P: 224-226°C. Yield: 76%. Chemical formula: C₂₆H₂₃N₅O₆. FT-IR (KBr, cm^{-1}): 1689 (C=O), 1559 (CH=N), 1125 (Ar-O). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 3.72 (s, 3H, OCH₃), 3.88 (s, 6H, 2OCH₃), 7.01(s, 2H, Ar-H), 7.37 (t, 1H, Ar-H, J = 7.24 Hz), 7.54 (t, 2H, Ar-H, J = 7.8 Hz), 7.83 (t, 1H, Ar-H, J = 7.96 Hz), 8.03 (d, 2H, Ar-H, J = 8.0 Hz), 8.34 (d, 1H, Ar-H, J = 7.92 Hz), 8.43 (d, 1H, Ar-H, J = 8.16 Hz), 8.59 (s, 1H, CH=N), 8.72 (s, 1H, Ar-H), 9.02 (s, 1H, Pyrazole-H), 11.96 (s, 1H, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 56.06, 60.07, 106.13, 116.68, 118.94, 122.23, 126.24, 127.03, 127.37, 127.66, 129.58, 130.29, 134.01, 134.92, 137.96, 138.99, 142.26, 147.79, 152.16, 153.01, 160.58. HRMS: Calculated for C₂₆H₂₃N₅O₆, 501.16, found: 502.1605 [M+H]⁺

(Z)-4-nitro-N'-((1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl) methylene) benzohydrazide (6h). Pale yellow solid, M.P: 243-245°C. Yield: 74%. Chemical formula: C₂₆H₂₃N₅O₆. FT-IR (KBr, cm^{-1}): 1681 (C=O), 1593 (CH=N), 1120 (Ar-O). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 3.73 (s, 3H, OCH₃), 3.89 (*3.84, s, 6H, 2OCH₃), 7.01 (* 6.88, s, 2H, Ar-H), 7.39 (t, 1H, Ar-H, J = 7.2 Hz), 7.55 (t, 2H, Ar-H, J = 7.6 Hz), 8.04 (*7.93, d, 3H, Ar-H, J = 8.0 Hz), 8.14 (*8.29, d, 2H, Ar-H, J = 8.8 Hz), 8.37 (d, 2H, Ar-H, J = 8.8 Hz), 8.60 (*8.70, s, 1H, CH=N), 9.03 (s, 1H, Pyrazole-H), 11.96 (br s, 1H, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 56.07, 60.09, 106.11, 116.68, 118.96, 123.65, 127.06, 127.37, 127.69, 129.10, 129.60, 137.97, 139.01, 139.24, 142.39, 149.22, 152.17, 153.02, 161.09. HRMS: Calculated for C₂₆H₂₃N₅O₆, 501.16, found: 502.1582 [M+H]⁺

2-phenyl-5-(1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl)-1, 3, 4-oxadiazole (7a): Off-white solid, M.P: 199-201°C. Yield: 73%. Chemical formula: C₂₆H₂₂N₄O₄. FT-IR (KBr, cm^{-1}): 1588 (C=N), 1124 (Ar-O). ^1H NMR (400 MHz, CDCl₃, δ ppm): 3.92 (s, 6H, 2OCH₃), 3.93 (s, 3H, OCH₃), 7.32 (s, 2H, Ar-H), 7.38-

7.41 (m, 1H, Ar-H), 7.47-7.55 (m, 5H, Ar-H), 7.83-7.85 (m, 2H, Ar-H), 7.99-8.01 (m, 2H, Ar-H), 8.66 (s, 1H, Pyrazole-H). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 55.99, 60.12, 105.83, 106.38, 119.02, 123.27, 126.45, 126.78, 127.48, 129.37, 129.68, 131.46, 131.99, 138.24, 138.66, 150.38, 152.64, 159.60, 163.09. HRMS: Calculated for C₂₆H₂₂N₄O₄, 454.16, found: 455.1639 [M+H]⁺

2-(1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl)-5-(o-tolyl)-1, 3, 4-oxadiazole (7b): Off-white solid, M.P: 204-206°C. Yield: 90%. Chemical formula: C₂₇H₂₄N₄O₄. FT-IR (KBr, cm⁻¹): 1584 (C=N), 1120 (Ar-O). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.61 (s, 3H, Ar-CH₃), 3.73 (s, 3H, OCH₃), 3.81 (s, 6H, 2OCH₃), 7.35-7.46 (m, 5H, Ar-H), 7.48-7.52 (m, 1H, Ar-H), 7.59 (t, 2H, Ar-H, J = 7.72 Hz), 7.94 (d, 1H, Ar-H, J = 7.72 Hz), 8.05 (d, 2H, Ar-H, J = 7.92 Hz), 9.43 (s, 1H, Pyrazole-H). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 21.47, 56.01, 60.12, 105.89, 106.48, 119.09, 122.37, 126.33, 126.87, 127.48, 128.71, 129.68, 131.30, 131.43, 131.75, 137.67, 138.24, 138.69, 150.55, 152.65, 159.11, 163.42. HRMS: Calculated for C₂₇H₂₄N₄O₄, 468.18, found: 469.1665 [M+H]⁺

2-(1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl)-5-(3, 4, 5-trimethoxyphenyl)-1, 3, 4-oxadiazole (7c): Off-white solid, M.P: 177-179°C. Yield: 83%. Chemical formula: C₂₉H₂₈N₄O₇. FT-IR (KBr, cm⁻¹): 1588 (C=N), 1122 (Ar-O). ¹H NMR (400 MHz, CDCl₃, δ ppm): 3.91 (s, 18H, 6OCH₃), 7.18 (s, 2H, Ar-H), 7.24 (d, 2H, Ar-H, J = 12.36 Hz), 7.40 (t, 1H, Ar-H, J = 7.2 Hz), 7.54 (t, 2H, Ar-H, J = 7.64 Hz), 7.85 (d, 2H, Ar-H, J = 7.96 Hz), 8.69 (s, 1H, Pyrazole-H). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 55.98, 56.09, 60.09, 60.24, 103.84, 105.86, 106.40, 118.42, 119.11, 126.87, 127.50, 129.68, 131.24, 138.17, 138.66, 140.58, 150.46, 152.59, 153.47, 159.49, 162.95. HRMS: Calculated for C₂₉H₂₈N₄O₇, 544.20, found: 545.1902 [M+H]⁺

2-(2-bromophenyl)-5-(1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl)-1, 3, 4-oxadiazole (7d): Off-white solid, M.P: 209-211°C. Yield: 73%. Chemical formula: C₂₆H₂₁BrN₄O₄. FT-IR (KBr, cm⁻¹): 1586 (C=N), 1123 (Ar-O). ¹H NMR (400 MHz, CDCl₃, δ ppm): 3.91 (s, 3H, OCH₃), 3.93 (s, 6H, 2OCH₃), 7.35-7.49 (m, 5H, Ar-H), 7.54 (t, 2H, Ar-H, J = 7.6 Hz), 7.75 (d, 1H, Ar-H, J = 7.92 Hz), 7.84 (d, 2H, Ar-H, J = 7.76 Hz), 7.92-7.94 (dd, 1H, Ar-H, J = 1.52, 7.68 Hz), 8.64 (s, 1H, Pyrazole-H). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 56.00, 60.11, 105.56, 106.45, 119.15, 119.29, 120.85, 124.52, 126.69, 127.54, 128.17, 128.51, 129.68, 131.48, 131.61, 133.28, 134.39, 138.26, 138.64, 150.59, 152.66, 159.93, 162.03. HRMS: Calculated for C₂₆H₂₁BrN₄O₄, 532.07, found: 533.0682 [M+H]⁺

2-(2,5 dichlorophenyl)-5-(1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl)-1, 3, 4-oxadiazole (7e): Off-white solid, M.P: 219-221°C. Yield: 79%. Chemical formula: C₂₆H₂₀Cl₂N₄O₄. FT-IR (KBr, cm⁻¹): 1586 (C=N), 1120 (Ar-O). ¹H NMR (400 MHz, CDCl₃, δ ppm): 3.92 (s, 3H, OCH₃), 3.93 (s, 6H, 2OCH₃), 7.32 (s, 2H, Ar-H), 7.39-7.44 (m, 2H, Ar-H), 7.48 (d, 1H, Ar-H, J = 8.6 Hz), 7.54 (t, 2H, Ar-H, J = 7.6 Hz), 7.84 (d, 2H, Ar-H, J = 7.72 Hz), 8.01 (d, 1H, Ar-H, J = 2.4 Hz), 8.65 (s, 1H, Pyrazole-H). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 56.01, 60.10, 105.49, 106.50, 119.17, 123.88, 126.71, 127.58, 129.69, 130.21, 130.55, 131.65, 132.29, 132.69, 133.03, 138.27, 138.63, 150.66, 152.65, 160.02, 160.17. HRMS: Calculated for C₂₆H₂₀Cl₂N₄O₄, 522.09, found: 523.0849 [M+H]⁺

2-(3, 5-dichlorophenyl)-5-(1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl)-1, 3, 4-oxadiazole (7f): Off-white solid, M.P: 181-183°C. Yield: 81%. Chemical formula: C₂₆H₂₀Cl₂N₄O₄. FT-IR (KBr, cm⁻¹): 1589 (C=N), 1129 (Ar-O). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 3.74 (s, 3H, OCH₃), 3.84 (s, 6H, 2OCH₃), 7.42-7.45 (m, 3H, Ar-H), 7.60 (t, 2H, Ar-H, J = 7.72 Hz), 7.92 (t, 1H, Ar-H, J = 1.8 Hz), 8.02-8.05 (m, 4H, Ar-H), 9.52 (s, 1H, Pyrazole-H). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 56.01, 60.13, 105.58, 106.46, 119.05, 124.88, 126.49, 126.68, 127.58, 129.71, 131.24, 131.83, 135.24, 138.29, 138.59, 150.43, 152.64, 160.26, 160.91. HRMS: Calculated for C₂₆H₂₀Cl₂N₄O₄, 522.09, found: 523.0869 [M+H]⁺

2-(3-nitrophenyl)-5-(1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl)-1, 3, 4-oxadiazole (7g): Pale yellow solid, M.P: 176-178°C. Yield: 77%. Chemical formula: C₂₆H₂₁N₅O₆. FT-IR (KBr, cm⁻¹): 1590 (C=N), 1514 (Ar-NO₂), 1126 (Ar-O). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 3.75 (s, 3H, OCH₃), 3.83 (s, 6H, 2OCH₃), 7.42-7.45 (m, 3H, Ar-H), 7.60 (t, 2H, Ar-H, J = 7.64 Hz), 7.92 (t, 1H, Ar-H, J = 8.04 Hz), 8.05 (d, 2H, Ar-H, J = 7.84 Hz), 8.47 (d, 2H, Ar-H, J = 7.92 Hz), 8.71 (s, 1H, Ar-H), 9.53 (s, 1H, Pyrazole-H). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 55.99, 60.10, 105.54, 106.40, 119.08, 120.85, 124.83, 126.32, 126.68, 127.55, 129.69, 131.28, 131.76, 132.45, 138.29, 138.61, 148.28, 150.46, 152.65, 160.26, 161.59. HRMS: Calculated for C₂₆H₂₁N₅O₆, 499.15, found: 500.1482 [M+H]⁺

2-(4-nitrophenyl)-5-(1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl)-1, 3, 4-oxadiazole (7h): Pale yellow solid, M.P: 219-221°C. Yield: 70%. Chemical formula: C₂₆H₂₁N₅O₆. FT-IR (KBr, cm⁻¹): 1594 (C=N), 1517 (Ar-NO₂), 1120 (Ar-O). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 3.76 (s, 3H, OCH₃), 3.84 (s, 6H, 2OCH₃), 7.44-7.47 (m, 3H, Ar-H), 7.61 (t, 2H, Ar-H, J = 8.0 Hz), 8.06 (d, 2H, Ar-H, J = 8.0 Hz),

8.30 (d, 2H, Ar-H, J = 8.8 Hz), 8.46 (d, 2H, Ar-H, J = 8.8 Hz), 9.52 (s, 1H, Pyrazole-H). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 56.07, 60.17, 105.58, 106.44, 119.09, 124.65, 126.66, 127.63, 127.77, 128.91, 129.77, 131.89, 138.35, 138.64, 149.21, 150.52, 152.69, 160.57, 161.83. HRMS: Calculated for C₂₆H₂₁N₅O₆, 499.15, found: 500.1472 [M+H]⁺

ANTIMICROBIAL EVALUATION⁵⁴

Antibacterial Activity Test Microorganisms and Growth Media *Staphylococcus aureus* (MTCC 3160), *Bacillus cereus* (MTCC 1305), *E.Coli* (MTCC 443) and *Pseudomonas aeruginosa* (MTCC 2453) and *Candida albicans* were selected based on their clinical and pharmacological importance. The bacterial strains obtained from Department of Microbiology, Osmania University, were employed for evaluating antibacterial activity. The bacterial stock cultures were incubated for 24 h at 37°C on nutrient agar. The bacteria were grown on Mueller-Hinton agar plates at 37°C. The stock culture was maintained at 4°C. for the growth of fungi potato dextrose agar was used. Whatman No.1 filter paper discs of 5mm diameter were autoclaved by keeping in a clean and dry Petri plate. The discs were soaked in compound solutions for 5 h were taken as test material. After 5 h the discs were shade dried. The concentrations of compound solutions per disc are accounted for 0.1 g/ml. Subsequently, they were carefully transferred to spread on cultured Petri plates. Filter paper discs immersed in ethanol, hexane, benzene and distilled water are prepared and used as control. To test the antibacterial activity, LB agar medium was prepared and the medium was sterilized at 121°C for 30 mins. The agar plates were prepared by pouring about 10ml of the medium into 10cm petri dishes under aseptic condition and left undisturbed for 2 h to solidify the medium. 1ml of inoculum (containing suspension) of *Staphylococcus aureus*, *Bacillus subtilis*, *E.Coli* and was poured on to the plates separately containing solidified agar media. The prepared sterile filter paper discs were impregnated with the compound solutions and shaken thoroughly and these test plates incubated for a period of 48 hrs in BOD at 37°C for the development of inhibitory zones and the average of 2 independent readings for each organism in different compound solutions were recorded. The inhibition zones were measured after 1 day at 37°C for bacteria. The diameter of the inhibition zone was measured and recorded with the aid of plastic ruler. Five paper discs placed in one Petri plate.

ANTIOXIDANT EVALUATION⁵⁵

The DPPH radical-scavenging activity was determined by using the method proposed by Yen and Chen (1995). DPPH (100 μM) was dissolved in pure ethanol (96%). The radical stock solution was prepared fresh daily. The DPPH solution (1 ml) was added to 1 ml of polyphenol extracts with 3 ml of ethanol. The mixture was shaken vigorously and allowed to stand at room temperature in the dark for 10 min. The decrease in absorbance of the resulting solution was monitored at 517 nm at 10 min. The results were corrected for dilution and expressed in μM Trolox per 100 g dry weight (dw). All determinations were performed in triplicate. 2, 6-bis (1, 1-dimethylethyl)-4-methylphenol (BHT) antioxidant agents was used as positive control.

RESULTS AND DISCUSSION

Chemistry

The route for the synthesis of 2, 5-substituted 1, 3, 4-oxadiazole derivatives (7a-h) is depicted in **Scheme 1** which involves four steps. Initially, the starting material 3,4,5-trimethoxy acetophenone **1** was treated with phenyl hydrazine **2** using acetic acid and methanol as a solvent at reflux temperature to obtain the acetophenone phenylhydrazone derivative **3** in 96% yield. In the second step the acetophenone phenylhydrazone derivative **3** was treated with Vilsmeier-Haack reagent (DMF-POCl₃) to obtain 1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazole carboxaldehyde **4** in 50% yield. The obtained pyrazole carboxaldehyde intermediate **4** was treated with different aryl hydrazides (**5a-h**) in the presence of ethanol at reflux temperature to obtain the corresponding hydrazone derivatives (**6a-h**) which underwent iodine catalysed cyclisation using potassium carbonate as base and DMSO as solvent to afford the title compounds (**7a-h**) in 70-90% yield. All the compounds synthesized were well characterized by IR, ¹H NMR, ¹³C NMR and HRMS spectral analysis. It is considerable to note that hydrazones derivatives were found to be present as a mixture of two rotameric forms in solution.⁵⁶ e.g. antiperiplanar (*ap*) and synperiplanar (*sp*) as indicated by their ¹H NMR spectra. The ¹H NMR spectra of the hydrazone compounds **6a**, **6d**, **6e** and **6h** revealed the duplication of some signals indicating the presence of rotamers.

Antimicrobial activity

The title compounds (**6a-h**) and (**7a-h**) were evaluated for their antimicrobial activity using *Escherichia Coli* (MTCC 443) and *Pseudomonas aeruginosa* (MTCC 2453) as g negative bacterial strains and *Staphylococcus aureus* (MTCC 3160), *Bacillus cereus* (MTCC 1305) as g posi-

Table 1: Antimicrobial activity (zone of inhibition in mm) of compounds 6a–h at various concentrations (200, 300 and 500 µg/mL).

Compound	Antibacterial activity (conc., µg/mL)												Antifungal activity		
	G negative bacteria						G positive bacteria						C.albicans		
	E.coli (MTCC 443)			P. aeruginosa (MTCC 2453)			S.aureus (MTCC 3160)			B. cereus (MTCC 1305)					
	200	300	500	200	300	500	200	300	500	200	300	500	200	300	500
6a	6	8	10	4	5	8	1	2	3	3	5	7	3	5	7
6b	4	6	8	-	-	-	8	9	12	3	5	7	-	-	-
6c	-	-	-	5	7	9	-	-	-	-	-	-	-	-	-
6d	-	-	-	-	-	-	9	11	12	-	-	-	6	7	8
6e	-	-	-	-	-	-	6	7	8	1	2	3	5	6	7
6f	4	6	8	3	4	5	8	8	12	2	4	5	-	-	-
6g	-	-	-	5	7	8	-	-	-	-	-	-	-	-	-
6h	-	-	-	5	8	9	-	-	-	-	-	-	1	2	3
Streptomycin	8	9	11	7	9	10	9	10	13	7	8	9	9	9	10

Table 2: Antimicrobial activity (zone of inhibition in mm) of compounds 7a–h at various concentrations (200, 300 and 500 µg/mL).

Compound	Antibacterial activity												Antifungal activity		
	G negative bacteria						G positive bacteria						C.albicans		
	E.coli (MTCC 443)			P. aeruginosa (MTCC 2453)			S.aureus (MTCC 3160)			B. cereus (MTCC 1305)					
	200	300	500	200	300	500	200	300	500	200	300	500	200	300	500
7a	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7b	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7c	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7d	-	-	-	2	3	4	-	-	-	-	-	-	-	-	-
7e	3	4	5	-	-	-	3	4	5	1	2	3	3	4	6
7f	-	-	-	-	-	-	-	-	-	2	3	4	-	-	-
7g	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7h	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Streptomycin	7	8	10	8	9	10	9	10	11	8	8	9	9	9	10

tive bacterial strains at different concentration levels of 200, 300 and 500 µg with Streptomycin as standard drug. The related antibacterial activities of the hydrazone derivatives are present in Table 1. The compounds **6b**, **6d** and **6f** are found to have high activity at all concentrations over g positive *staphylococcus aureus*. Compound **6a** exhibited considerable activity over g negative bacterial strain *E.Coli* at all concentrations. Compounds **6c** and **6h** have responded with activity over g negative *P. aeruginosa* at 300 and 500 µg concentrations compared to the standard drug. The antifungal activity studies revealed that compound **6d** has potential activity while compounds **6a** and **6e** have moderate activities and compound **6h** showed weak activity against the fungi *C.albicans*. When compared to the standard (BHT).

The *in vitro* antibacterial studies of the oxadiazoles **7a-h** (Table 2) revealed that compound **7e** is moderate in activity while the remaining compounds did not announce any activity. The antifungal activity of the compounds **7a-h** revealed that compound **7e** exhibited good activity over the fungal species *C.albicans* at 500 µg concentration while all the other remaining compounds are inert in activity. Based on the analytical results, it is evident that compound **6d** (2-bromo substituted pyrazole hydrazone derivative) is a potential agent with significant antimicrobial activity.

Anti-oxidant activity

The antioxidant activity of the hydrazone and oxadiazole derivatives was evaluated using DPPH radical

Table 3: Antioxidant activity of compounds 6a-h by DPPH method.

Compound	Scavenging activity (IC ₅₀ , μM)					
	25 μM	50 μM	75 μM	100 μM	125 μM	250 μM
6a	11.9 \pm 1.53	25.7 \pm 1.23	36.1 \pm 1.32	38.5 \pm 1.42	39.4 \pm 1.18	69.7 \pm 1.12
6b	15.4 \pm 1.30	27.7 \pm 1.24	38.6 \pm 1.23	39.3 \pm 1.36	39.5 \pm 1.32	69.8 \pm 1.43
6c	-	-	-	-	-	-
6d	-	-	-	-	37.34 \pm 1.54	68.26 \pm 1.32
6e	12.2 \pm 1.03	22.9 \pm 1.22	34.3 \pm 1.47	35.2 \pm 1.39	35.5 \pm 1.35	66.9 \pm 1.54
6f	13.9 \pm 1.10	25.8 \pm 1.15	36.4 \pm 1.30	36.9 \pm 1.43	37.4 \pm 1.34	68.3 \pm 1.36
6g	-	-	-	-	-	-
6h	-	-	-	-	-	-
Control (BHT)	18.40 \pm 0.55	28.28 \pm 1.20	42.32 \pm 1.24	45.35 \pm 1.32	47.28 \pm 1.44	76.38 \pm 1.32

Table 4: Antioxidant activity of compounds 7a-h by DPPH method

Compound	Scavenging activity (IC ₅₀ , μM)					
	25 μM	50 μM	75 μM	100 μM	125 μM	250 μM
7a	-	-	-	-	-	-
7b	-	-	-	-	-	-
7c	-	-	-	-	-	-
7d	-	-	-	-	35.5 \pm 1.25	66.9 \pm 1.48
7e	13.9 \pm 1.45	25.4 \pm 1.34	36.5 \pm 1.25	38.1 \pm 1.37	39.2 \pm 1.28	69.9 \pm 1.32
7f	15.4 \pm 1.12	25.8 \pm 1.32	36.6 \pm 1.44	38.8 \pm 1.33	39.7 \pm 1.47	69.8 \pm 1.29
7g	-	-	-	-	-	-
7h	-	-	-	-	-	-
Control (BHT)	18.40 \pm 0.55	28.28 \pm 1.20	42.32 \pm 1.24	45.35 \pm 1.32	47.28 \pm 1.44	76.38 \pm 1.32

scavenging method using 2, 6-bis (1, 1-dimethylethyl)-4-methylphenol (BHT) as standard.

The DPPH radical scavenging activity results of the hydrazone derivatives (**6a-h**) at different concentrations are depicted in Table 3. The activity studies revealed that the compounds **6a**, **6b**, **6e** and **6f** exhibited strong antioxidant activities in all concentrations when compared to the standard BHT. Among the active compounds, compounds **6a** (the phenyl substituted derivative) and compound **6e** (the 2, 5-dichloro substituted derivative) showed excellent activities, compound **6a** being the most potent compound. Next to **6a** and **6e**, compounds **6b** and **6f** exhibited promising activities while compound **6d** showed good activity at 125 μM and 250 μM concentrations. The order of radical scavenging activities of these compounds is in the order **6a**>**6e**>**6f**>**6b**>**6d**. All the remaining compounds announced non antioxidant activity.

The DPPH radical scavenging activity results of the oxadiazole derivatives (**7a-h**) at different concentrations are depicted in Table 4. From the Table, it is evident that the compounds **7e** (2, 5-dichloro) and **7f** (3, 5-dichloro)

exhibited excellent anti oxidant activities, compound **7e** being the most potent compound when compared to the standard BHT. Compound **7d** showed good activity at 125 μM and 250 μM concentrations while the remaining compounds announced non- antioxidant activity.

CONCLUSION

Screening of compounds **6a-h** and **7a-h** invitro for their anti-microbial activity against Streptomycin as control drug indicated that the compound **6d** (2-bromo substituted pyrazole hydrazone derivative) is antimicrobial potent. The antioxidant evaluation of the same series of compounds using DPPH radical scavenging method revealed that compounds **6a**, **6e**, **7e** and **7f** announced strong activities when compared to the control BHT.

ACKNOWLEDGEMENT

The authors sincerely express their gratitude Dr. P. Yadagiri Reddy, CEO, Escientia Bio Pharma Pvt. Ltd, Hyderabad for his encouragement in completing the present research work. The authors extend their sincere thanks

to Dr. D. Jayasimharayalu, Director, Global institute of Bio Technology, Himayathnagar, Hyderabad for his cooperation in carrying out the anti bacterial and anti oxidant studies.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

ABBREVIATIONS USED


TLC: Thin layer chromatography; **FT-IR:** Fourier transform infrared spectroscopy; **NMR:** Nuclear magnetic resonance spectroscopy; **DMSO-d₆:** Deuterated dimethyl sulphoxide; **HRMS:** High resolution mass spectrometry; **M.P:** Melting Point; **DPPH:** 2, 2-diphenyl-1-picrylhydrazyl; **BHT:** 2, 6-bis (1, 1-dimethylethyl)-4-methylphenol; **BOD:** Bio Chemical Oxygen Demand.

REFERENCES

- Shi W, Qian X, Song G, Zhang R, Li R. Syntheses and insecticidal activities of novel 2-fluorophenyl-5-aryl/cyclopropyl-1, 3, 4-oxadiazoles. *J Fluorine Chem.* 2000; 106(2):173-9. [https://doi.org/10.1016/S0022-1139\(00\)00323-7](https://doi.org/10.1016/S0022-1139(00)00323-7).
- Diana GD, Volkots DL, Nitz TJ, Bailey TR, Long MA, Vescio N, Aldous S, *et al.*, Oxadiazoles as ester bioisosteric replacements in compounds related to disoxaril. Antirhinovirus activity. *J Med Chem.* 1994; 37(15):2421-36. <https://doi.org/10.1021/jm00041a022>. PMID: 8057290.
- Behalo MS. An efficient one-pot catalyzed synthesis of 2, 5-disubstituted-1, 3, 4-oxadiazoles and evaluation of their antimicrobial activities. *RSC Adv.* 2016; 6(105):03132-6. <https://doi.org/10.1039/C6RA22663A>.
- Mihailovic N, Markovic V, Matic IZ, Stanisavljevic NS, Jovanovic ZS, Trifunovic S, *et al.*, Synthesis and antioxidant activity of 1, 3, 4-oxadiazoles and their diacylhydrazine precursors derived from phenolic acids. *RSC Adv.* 2017; 7(14): 8550-60. <https://doi.org/10.1039/C6RA28787E>.
- Gamal El-Din MM, El-Gamal MI, Abdel-Maksoud MS, Yoo KH, Oh CH. Synthesis and *in vitro* antiproliferative activity of new 1, 3, 4-oxadiazole derivatives possessing sulfonamide moiety. *Eur J Med Chem.* 2015; 90:45-52. <https://doi.org/10.1016/j.ejmech.2014.11.011>. PMID: 25461310.
- Rajak H, Singour P, Kharya MD, Mishra P. A novel series of 2, 5-disubstituted 1, 3, 4-oxadiazoles: Synthesis and SAR study for their anticonvulsant activity. *Chem Biol Drug Des.* 2011; 77(2):152-8. <https://doi.org/10.1111/j.1747-0285.2010.01066.x>. PMID: 21266018.
- Dhumal ST, Deshmukh AR, Bhosle MR, Khedkar VM, Nawale LU, Sarkar D, *et al.*, Synthesis and antitubercular activity of new 1, 3, 4-oxadiazoles bearing pyridyl and thiazolyl scaffolds. *Bioorg Med Chem Lett.* 2016; 26(15):3646-51. <https://doi.org/10.1016/j.bmcl.2016.05.093>. PMID: 27301367.
- Wu W, Chen Q, Tai A, Jiang G, Ouyang G. Synthesis and antiviral activity of 2-substituted methylthio-5-(4-amino-2-methylpyrimidin-5-yl)-1, 3, 4-oxadiazole derivatives. *Bioorg Med Chem. Lett.* 2015; 25(10): 2243-6. <https://doi.org/10.1016/j.bmcl.2015.02.069>. PMID: 25900217.
- Zareef M, Iqbal R, De Dominguez NG, Rodrigues J, Zaidi JH, Arfan M, *et al.*, Synthesis and antimalarial activity of novel chiral and achiral benzenesulfonamides bearing 1, 3, 4-oxadiazole moieties. *J Enzyme Inhib Med Chem.* 2007; 22(3):301-8. <http://dx.doi.org/10.1080/14756360601114569>. PMID: 17674812.
- Biju CR, Ilango K, Manju P, Rekha K. Design and microwave-assisted synthesis of 1, 3, 4-oxadiazole derivatives for analgesic and anti-inflammatory activity. *J Young Pharm.* 2012; 4(1):33-7. <https://doi.org/10.4103/0975-1483.93576>. PMID: PMC3326780.
- Plant HL, Regis RR, Moore RC. Substituted oxadiazole-Phosphate pesticide. 1985; *Eur. Pat. Appl.* EP 156,638 A2.
- Matthews IR, Bacon DP. Thia-and oxadiazole derivatives and their use as fungicides or insecticides. 1995; *PCT Int. Appl.* WO 9505368 A1.
- Kraatz U, Gallenkamp B, Marhold A, Wolfrum P, Andersch W, Erdelen C, *et al.*, Heterocyclic Fluoroalkenyl Thioethers. 2002; *WO* 2002006256 A1.
- W. Wiedemann, *Chem. Z.* 106 (1982) 313.
- Gomes D, Borges CP, Pinto JC. Study of the synthesis of poly (4, 4'-diphenylether-1, 3, 4-oxadiazole) in solutions of poly (phosphoric acid). *Polymer.* 2001; 42(3):851-65. [https://doi.org/10.1016/S0032-3861\(00\)00458-4](https://doi.org/10.1016/S0032-3861(00)00458-4).
- Meier M, Buchwald E, Karg S, Posch P, Greczmiel M, Strohriegel P, *et al.*, Heterolayer light-emitting diodes based on new oxadiazole polymers. *Synth Met.* 1996; 76 : (1-3)95-9. [https://doi.org/10.1016/0379-6779\(95\)03426-K](https://doi.org/10.1016/0379-6779(95)03426-K)
- Malladi S, Isloor AM, Peethambar SK, Fun HK. Synthesis and biological evaluation of newer analogues of 2, 5-disubstituted 1, 3, 4-oxadiazole containing pyrazole moiety as antimicrobial agents. *Arab J Chem.* 2014; 7(6): 1185-91. <https://doi.org/10.1016/j.arabj.2013.12.020>.
- Renuka N, Vivek HK, Pavithra G, Ajay Kumar K. Synthesis of coumarin appended pyrazolyl-1, 3, 4-oxadiazoles and pyrazolyl-1, 3, 4-thiadiazoles: Evaluation of their *in vitro* antimicrobial and anti oxidant activities and molecular docking studies. *Russ J Bioorg Chem.* 2017; 43(2): 197-210. <https://doi.org/10.1134/S106816201702011X>.
- Kumar M, Kumar V, Beniwal V. Synthesis of some pyrazolylaldehyde N-isonicotinoyl hydrazones and 2, 5-disubstituted 1, 3, 4-oxadiazoles as DNA photocleaving agents. *Med Chem Res.* 2015; 24(7): 2862-70. <https://doi.org/10.1007/s00044-015-1340-x>.
- Puthiyapurayil P, Poojary B, Chikkanna C, Buridipad SK. Design, synthesis and biological evaluation of a novel series of 1, 3, 4-oxadiazole bearing N-methyl-4-(trifluoromethyl) phenyl pyrazole moiety as cytotoxic agents. *Eur J Med Chem.* 2012; 53:203-10. <https://doi.org/10.1016/j.ejmech.2012.03.056>. PMID: 22542958.
- Bansal S, Bala M, Suthar SK, Choudhary S, Bhattacharya S, Bhardwaj V, *et al.*, Design and synthesis of novel 2-phenyl-5-(1, 3-diphenyl-1H-pyrazol-4-yl)-1, 3, 4-oxadiazoles as selective COX-2 inhibitors with potent anti-inflammatory activity. *Eur J Med Chem.* 2014; 80:167-74. <https://doi.org/10.1016/j.ejmech.2014.04.045>. PMID: 24780593
- Farghaly AR, El-Kashef H. Synthesis of some new azoles with antiviral potential. *ARKIVOC.* 2006; 11:76-90. <https://doi.org/10.3998/ark.5550190.0007.b07>.
- Rollas S, Kucukguzel SG. Biological Activities of hydrazone derivatives. *Molecules.* 2007; 12(8):1910-39. <https://doi.org/10.3390/12081910>. PMID: 17960096
- Ajani OO, Obafemi CA, Nwinyi OC, Akinpelu DA. Microwave assisted synthesis and antimicrobial activity of 2-quinoxalinone-3-hydrazone derivatives. *Bioorg Med Chem.* 2010; 18(1):214-21. <https://doi.org/10.1016/j.bmc.2009.10.064>. PMID: 19948407.
- El-Bayoumi MA, El-Aasser M, Abdel-Halim F. Electronic spectra and structures of Schiff's bases. I. Benzanils. *J Am Chem Soc.* 1971; 93(3):586-90. <https://doi.org/10.1021/ja00732a004>.
- Jedlovská E, Lesko J. A simple one-pot procedure for the synthesis of 1, 3, 4-Oxadiazoles. *Synth Commun.* 1994; 24(13): 1879-85. <http://dx.doi.org/10.1080/00397919408010196>.
- Popielek L. Hydrazide-hydrazones as potential antimicrobial agents: overview of the literature since 2010. *Med Chem Res.* 2017; 26(2):287-01. DOI 10.1007/s00044-016-1756-y. PMID: PMC5250660.
- Belkheiri N, Bouguerne B, Bedos-Belval F, Duran H, Bernis C, Salvayre R, *et al.*, Synthesis and antioxidant activity evaluation of a synergic hydrazones family. *Eur J Med Chem.* 2010; 45(7):3019-26. <https://doi.org/10.1016/j.ejmech.2010.03.031>. PMID: 20403645.
- Angelova VT, Valcheva V, Pencheva T, Voynikov Y, Vassilev N, Mihaylova R, *et al.*, Synthesis, antimicrobial activity and docking study of 2-aro[1] benzopyrano[4,3-c]pyrazol-4(1H)-one derivatives and related hydrazide-hydrazones. *Bioorg Med Chem Lett.* 2017; 27(13):2996-3002. <https://doi.org/10.1016/j.bmcl.2017.05.011>. PMID: 28512022.
- Demirbas N, Karaoglu SA, Demirbas A, Sancak K. Synthesis and antimicrobial activities of some new 1-(5-phenylamino-[1,3,4]thiadiazol-2-yl)methyl-5-oxo-[1,2,4]triazole and 1-(4-phenyl-5-thioxo-[1,2,4]triazol-3-yl)-methyl-5-oxo-[1,2,4] triazole derivatives. *Eur J Med Chem.* 2004; 39(9):793-804. <https://doi.org/10.1016/j.ejmech.2004.06.007>. PMID: 15337292

31. Li ZH, Yang DX, Geng PF, Zhang J, Wei HM, Hu B, *et al.*. Design, synthesis and biological evaluation of [1, 2, 3]triazolo[4,5-d]pyrimidine derivatives possessing a hydrazone moiety as antiproliferative agents. *Eur J Med Chem.* 2016; 124:967-80. <https://doi.org/10.1016/j.ejmech.2016.10.022>. PMID: 27771599
32. Kumar N, Chauhan LS, Sharma CS, Dashora N, Bera R. Synthesis, analgesic and anti-inflammatory activities of chalconyl-incorporated hydrazone derivatives of mefenamic acid. *Med Chem Res.* 2015; 24(6):2580-90. <https://doi.org/10.1007/s00044-015-1318-8>.
33. Liu Y, Lu B, Lu J, Xin C, Li J, Mu J, *et al.*. Synthesis and antibacterial activities of N-[(1-aryl-3-phenyl-pyrazol-4-yl) methylene]-2-(halo-o-hydroxyphenyl) hydrazide derivatives. *Chem Res Chin Univ.* 2013; 29(3):449-53. <https://doi.org/10.1007/s40242-013-2491-2>.
34. Yang XD. Synthesis and biological activity of hydrazone derivatives containing pyrazole. *J Chem Res.* 2008; 9:489-91. <https://doi.org/10.3184/030823408X340799>.
35. Xing M, Zhao TT, Ren YJ, Peng NN, Yang XH, Li X, *et al.*. Synthesis, biological evaluation, and molecular docking studies of pyrazolyl-acylhydrazone derivatives as novel anticancer agents. *Med Chem Res.* 2014; 23(7):3274-86. <https://doi.org/10.1007/s00044-014-0909-0>.
36. Nasrullah M, Khan MA, Khan MN, Humphrey MG, Nasim FH, Chaudhry F, *et al.*. Diaryl pyrazole-4-carbaldehyde benzoylhydrazones metal complexes: Synthesis and their antibacterial and antioxidant screening. *Asian J Chem.* 2013; 25(1):419-23. <https://doi.org/10.14233/ajchem.2013.13131>.
37. El-Sayed MA, Abdel-Aziz NI, Abdel-Aziz AA, El-Azab AS, Asiri YA, ElTahir KEH. Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study. *Bioorg Med Chem.* 2011; 19(11):3416-24. <https://doi.org/10.1016/j.bmc.2011.04.027>. PMID: 21570309.
38. Abadi AH, Eissa AAH, Hassan GS. Synthesis of novel 1, 3, 4-trisubstituted pyrazole derivatives and their evaluation as antitumor and antiangiogenic agents. *Chem Pharm Bull.* 2003; 51(7):838-44. <http://doi.org/10.1248/cpb.51.838>. PMID: 12843591.
39. Fraga AGM, Rodrigues CR, Miranda ALP, Barreiro EJ, Fraga CAM. Synthesis and pharmacological evaluation of novel heterocyclic acylhydrazone derivatives, designed as PAF antagonists. *Eur J Pharm Sci.* 2000; 11(4):285-90. [https://doi.org/10.1016/S0928-0987\(00\)00102-0](https://doi.org/10.1016/S0928-0987(00)00102-0). PMID: 11033071.
40. Bandgar BP, Totre JV, Gawande SS, Khobragade CN, Warangkar SC, Kadam PD. Synthesis of novel 3, 5-diaryl pyrazole derivatives using combinatorial chemistry as inhibitors of tyrosinase as well as potent anticancer, anti-inflammatory agents. *Bioorg Med Chem.* 2010; 18(16):6149-55. <https://doi.org/10.1016/j.bmc.2010.06.046>. PMID: 20638287
41. Ragavan RV, Vijayakumar V, Kumari NS. Synthesis and antimicrobial activities of novel 1, 5-diaryl pyrazoles. *Eur J Med Chem.* 2010; 45(3):1173-80. <https://doi.org/10.1016/j.ejmech.2009.12.042>. PMID: 20053480.
42. Bellam M, Gundluru M, Sarva S, Chadive S, Netala VR, Tartte V, *et al.*. Synthesis and antioxidant activity of some new N-alkylated pyrazole-containing benzimidazoles. *Chem Heterocycl Comp.* 2017; 53(2):173-78. <https://doi.org/10.1007/s10593-017-2036-6>.
43. Alegaon SG, Alagawadi KR, Garg MK, Dushyant K, Vinod D. 1, 3, 4-Trisubstituted pyrazole analogues as promising anti-inflammatory agents. *Bioorg Chem.* 2014; 54: 51-9. <https://doi.org/10.1016/j.bioorg.2014.04.001>. PMID: 24793214.
44. Pathak V, Maurya HK, Sharma S, Srivastava KK, Gupta A. Synthesis and biological evaluation of substituted 4, 6-diarylpyrimidines and 3, 5-diphenyl-4,5-dihydro-1H-pyrazoles as anti-tubercular agents. *Bioorg Med Chem Lett.* 2014; 24(13):2892-6. <https://doi.org/10.1016/j.bmcl.2014.04.094>. PMID: 24835631.
45. Ali AR, El-Bendary ER, Ghaly MA, Shehata IA. Synthesis, *in vitro* anticancer evaluation and *in silico* studies of novel imidazo[2,1-b]thiazole derivatives bearing pyrazole moieties. *Eur J Med Chem.* 2014; 75:492-500. <https://doi.org/10.1016/j.ejmech.2013.12.010>. PMID: 24576591.
46. El-Sabbagh OI, Baraka MM, Ibrahim SM, Pannecouque C, Andrei G, Snoeck R, *et al.*. Synthesis and antiviral activity of new pyrazole and thiazole derivatives. *Eur J Med Chem.* 2009; 44(9):3746-53. <https://doi.org/10.1016/j.ejmech.2009.03.038>. PMID: 19419804.
47. Abdel-Aziz M, Abuo-Rahma Gel-D, Hassan AA. Synthesis of novel pyrazole derivatives and evaluation of their antidepressant and anticonvulsant activities. *Eur J Med Chem.* 2009; 44(9):3480-7. <https://doi.org/10.1016/j.ejmech.2009.01.032>. PMID: 19268406.
48. Genin MJ, Biles C, Keiser BJ, Poppe SM, Swaney SM, Tarpley WG, *et al.*. Novel 1, 5-Diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: Lead identification and SAR of 3- and 4-substituted derivatives. *J Med Chem.* 2000; 43(5):1034-40. <https://doi.org/10.1021/jm990383f>. PMID: 10715167.
49. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, *et al.*. Synthesis and biological evaluation of the 1, 5-diarylpyrazole class of cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). *J Med Chem.* 1997; 40(9):1347-1365. <https://doi.org/10.1021/jm960803q>. PMID: 9135032.
50. Hote BS, Lokhande PD. Novel and efficient synthesis of 4-indazolyl-1, 3, 4-trisubstituted pyrazole derivatives. *Synth Commun.* 2014; 44(10):1492-500. <http://dx.doi.org/10.1080/00397911.2013.862724>.
51. Kumar BC, Reddy KRV, Khan F. Synthesis, characterization and antimicrobial activity of some new N1-substituted pyrazol-4-carbaldehyde bearing 2, 4-dichloro phenyl moiety. *J Pharm Sci.* 2013; 2(5):55-9. <http://dx.doi.org/10.7897/2277-4572.02578>.
52. Han S, Zhang FF, Xie X, Chen JZ. Design, synthesis, biological evaluation, and comparative docking study of 1, 2, 4-triazolones as CB1 receptor selective antagonists. *Eur J Med Chem.* 2014; 74: 73-84. <http://dx.doi.org/10.1016/j.ejmech.2013.12.018>. PMID: 24445310.
53. Yu W, Huang G, Zhang Y, Liu H, Dong L, Yu X, *et al.*. I₂-mediated oxidative C-O bond formation for the synthesis of 1, 3, 4-oxadiazoles from aldehydes and hydrazides. *J Org Chem.* 2013; 78(20):10337-43. <http://dx.doi.org/10.1021/jo401751h>. PMID: 24059837.
54. Rahman AU, Choudhary MI, Thomsen WJ. Bioassay techniques for drug development. Harwood academic publishers. Netherlands. Harwood academic publisher; 2001; 22:16.
55. Yen GC, Chen HY. Antioxidant activity of various tea extracts in relation to their antimutagenicity. *J Agric Food Chem.* 1995; 43(1):27-32. <http://dx.doi.org/10.1021/jf00049a007>.
56. Lopes AB, Miguez E, Kümmerle AE, Rumjanek VM, Fraga CA, Barreiro EJ. Characterization of amide bond conformers for a novel heterocyclic template of N-acylhydrazone derivatives. *Molecules* 2013; 18(10):11683-704; doi: 10.3390/molecules181011683. PMID: 24071978.

PICTORIAL ABSTRACT



About Authors



Dr. P.V.S. Machiraju is presently working as a professor of chemistry and Dean-R and D, Pragathi Engineering College (Autonomous) Surampalem, near Kakinada City, A.P. Research Interests: Include Organic, Analytical, Environmental and Bio Chemistry. Also in interdisciplinary with Hydrology, Microbiology, Nano Chemistry and Technology. He has 38 international and 6 national publications at his career.

SUMMARY

- A novel 1, 3, 4-oxadiazole substituted pyrazole scaffolds **7a-h** were synthesized by the iodine catalyzed oxidative cyclization of different hydrazone derivatives **6a-h** in good to excellent yields. The hydrazone derivatives **6a-h** were obtained by heating the corresponding aldehyde intermediate **4** in ethanol with various substituted aryl hydrazides. All the final compounds were characterized by IR, NMR and HRMS spectral analysis. The *invitro* antimicrobial activity of the synthesized compounds **6a-h** and **7a-h** were screened over two g negative bacterial strains *E.Coli*, *P. aeruginosa* and two g positive bacterial strains *S. aureus*, *B. cereus* with three different concentrations of 200, 300 and 500 $\mu\text{g/mL}$ using Streptomycin as standard drug. The study results revealed that the compounds **6a**, **6b**, **6d** and **6f** are with moderate to good antimicrobial activity. The compounds **6a**, **6d** and **6e** are found to have moderate to good antifungal activity. Finally the research study results revealed that the compound **6d** (2-bromo substituted pyrazole hydrazone derivative) as a potential antimicrobial agent. Furthermore, the antioxidant activity studies revealed that the compounds **6a**, **6e** and **7e**, **7f** exhibited potent anti oxidant activities when compared to the control drug BHT.

Cite this article: Ch.Krishna Prasad, Machiraju PVS. Synthesis and Characterization of 2-phenyl-5-(1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazol-4-yl) - 1, 3, 4-oxadiazole Scaffolds for Assessing Their Medicinal Potentials. Indian J of Pharmaceutical Education and Research. 2018;52(1):135-45.